submissions – Page 13

Hybrid paper-electronic workflows uncontrolled during system operation – 21 CFR Part 11 compliance gaps

Uncontrolled Hybrid Paper-Electronic Workflows: Compliance Gaps and Resolutions In today’s pharmaceutical landscape, the convergence of paper and electronic workflows presents unique challenges regarding compliance with 21 CFR Part 11. Pharmaceutical…

Hybrid paper-electronic workflows uncontrolled during system upgrade – preventing repeat Part 11 findings

Managing Uncontrolled Hybrid Paper-Electronic Workflows During System Upgrades The rapid digital transformation in pharmaceutical operations has fostered hybrid workflows that combine paper and electronic systems. However, improperly managed transitions can…

Hybrid paper-electronic workflows uncontrolled during validation lifecycle – preventing repeat Part 11 findings

Managing Uncontrolled Hybrid Paper-Electronic Workflows During Validation to Prevent Part 11 Findings In the rapidly evolving landscape of pharmaceutical manufacturing and regulatory compliance, addressing the challenges posed by hybrid paper-electronic…

Record retention failures during compliance audit – preventing repeat Part 11 findings

Preventing Repeat Findings from Record Retention Failures in Compliance Audits During compliance audits, record retention failures can trigger non-compliance issues, particularly related to 21 CFR Part 11 regarding electronic records.…

System access controls weak during validation lifecycle – preventing repeat Part 11 findings

Strengthening System Access Controls Throughout the Validation Lifecycle Pharmaceutical companies often face challenges related to system access controls, particularly during the validation lifecycle. Weak access controls can lead to significant…

ERES controls not implemented during inspection walkthrough – CAPA and revalidation strategy

Strategies for Addressing ERES Control Failures During Inspection Walkthroughs When regulatory inspectors notice lapses in electronic records and electronic signatures (ERES) controls during walkthroughs, it poses a significant risk for…

Record retention failures during inspection walkthrough – preventing repeat Part 11 findings

Preventing Record Retention Failures During Inspection Walkthroughs In the highly regulated pharmaceutical industry, maintaining adequate record retention practices is crucial for compliance during inspections. Given the heightened scrutiny from regulatory…

Electronic signatures misused during system operation – 21 CFR Part 11 compliance gaps

Addressing Compliance Gaps in Electronic Signature Use During System Operation The use of electronic signatures in pharmaceutical manufacturing and quality control envelops critical regulatory compliance under 21 CFR Part 11.…

Electronic signatures misused during system operation – inspection evidence requirements

“`html Addressing Misuses of Electronic Signatures During System Operation: A Practical Guide In today’s digital age, the misuse of electronic signatures during system operation is an increasingly pressing issue for…

Electronic signatures misused during system upgrade – preventing repeat Part 11 findings

Mitigating Risks of Misuse of Electronic Signatures During System Upgrades In the landscape of pharmaceutical manufacturing, the rise of electronic records and signatures is accompanied by significant compliance challenges. Misuse…

Electronic signatures misused during inspection walkthrough – inspection evidence requirements

Addressing Misuse of Electronic Signatures During Inspection Walkthroughs The use of electronic signatures (e-signatures) in pharmaceutical manufacturing has improved efficiency but also raised significant concerns regarding compliance and data integrity.…

Record retention failures during compliance audit – inspection evidence requirements

Addressing Record Retention Failures During Compliance Audits: A Practical Playbook In the pharmaceutical industry, record retention is paramount to ensuring compliance with regulatory requirements. Failures in this area can lead…